Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica

NCT07279688 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Polymyalgia Rheumatica (PMR)

Interventions

DRUG: Baricitinib 4 MG Oral Tablet
DRUG: Baricitinib 2 MG Oral Tablet
DRUG: Placebo 4 mg
DRUG: Placebo 2 mg

Sponsor

University Hospital, Brest

Collaborators

[object Object]